Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by S. Webster
Pdb71 - Assessing the Relative Cost-Effectiveness of Empagliflozin and Canagliflozin for the Treatment of Type 2 Diabetes Patients With Existing Cardiovascular Disease in the Uk
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Entry of Technetium-99 Into the Human Food Chain Through the Use of Seaweed as Soil Conditioner
Radioprotection
Risk
Sustainability
Mutagenesis
Renewable Energy
Public Health
Waste Management
Nuclear Energy
Disposal
Environmental
Engineering
Reliability
Safety
Toxicology
Health
Quality
the Environment
Occupational Health
Related publications
Pdb73 - Indirect Cost-Effectiveness Analysis of Empagliflozin Compared to Canagliflozin for Patients With T2dm and Cardiovascular Disease in the Spanish National Health Service
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Cost Effectiveness Evaluation of Canagliflozin in Combination With Metformin in the Treatment of Type 2 Diabetes Mellitus in Poland
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Clinical Implications of Canagliflozin Treatment in Patients With Type 2 Diabetes
Clinical Diabetes
Internal Medicine
Endocrinology
Metabolism
Diabetes
Pdb39 - Empagliflozin for Patients in the Netherlands With Type 2 Diabetes Mellitus and Established Cardiovascular Disease: A Budget Impact Model
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
The CANVAS Program: Implications of Canagliflozin on Reducing Cardiovascular Risk in Patients With Type 2 Diabetes Mellitus
Cardiovascular Diabetology
Internal Medicine
Cardiology
Endocrinology
Cardiovascular Medicine
Metabolism
Diabetes
Assessment of the Key Drivers of Cost-Effectiveness in the Economic Modelling of Canagliflozin (CANA) Versus Glimepiride (GLIM) in the Treatment of Type 2 Diabetes Mellitus (T2DM) in the UK Setting
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pdb63 - Cost-Effectiveness Analysis of Empagliflozin Treatment in Patients With Type 2 Diabetes and Chronic Heart Failure Based on Subgroup of Empa-Reg Outcome in the United Kingdom
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Effectiveness of Vazonat in the Comprehensive Therapy of Patients With Type 2 Diabetes Mellitus on the Background of Cardiovascular Disease
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY
Empagliflozin Promises to Bridge the Gap Between Non-Alcoholic Fatty Liver Disease, Type 2 Diabetes, and Cardiovascular Disease
Przeglad Gastroenterologiczny
Gastroenterology
